Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2022
This article has no abstract
Epistemonikos ID: 8e6115bb65ddbb213ae9c3d0856f0ef1bc13c5cd
First added on: Apr 11, 2025